Research ArticleCLINICAL INVESTIGATIONS
Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy
Daniel Putzer, Michael Gabriel, Benjamin Henninger, Dorota Kendler, Christian Uprimny, Georg Dobrozemsky, Clemens Decristoforo, Reto Josef Bale, Werner Jaschke and Irene Johanna Virgolini
Journal of Nuclear Medicine August 2009, 50 (8) 1214-1221; DOI: https://doi.org/10.2967/jnumed.108.060236
Daniel Putzer
Michael Gabriel
Benjamin Henninger
Dorota Kendler
Christian Uprimny
Georg Dobrozemsky
Clemens Decristoforo
Reto Josef Bale
Werner Jaschke
Irene Johanna Virgolini
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy
Daniel Putzer, Michael Gabriel, Benjamin Henninger, Dorota Kendler, Christian Uprimny, Georg Dobrozemsky, Clemens Decristoforo, Reto Josef Bale, Werner Jaschke, Irene Johanna Virgolini
Journal of Nuclear Medicine Aug 2009, 50 (8) 1214-1221; DOI: 10.2967/jnumed.108.060236
Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy
Daniel Putzer, Michael Gabriel, Benjamin Henninger, Dorota Kendler, Christian Uprimny, Georg Dobrozemsky, Clemens Decristoforo, Reto Josef Bale, Werner Jaschke, Irene Johanna Virgolini
Journal of Nuclear Medicine Aug 2009, 50 (8) 1214-1221; DOI: 10.2967/jnumed.108.060236
Related Articles
Cited By...
- 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection
- Safety, tolerability and clinical implementation of 'ready-to-use 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
- Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
- Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies
- Bone metastases and skeletal-related events from neuroendocrine tumors
- 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-Octreotide SPECT/CT, and Whole-Body MR Imaging in Detection of Neuroendocrine Tumors: A Prospective Trial
- Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification
- The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors
- Nuclear medicine imaging of neuroendocrine tumours
- Radiopeptide Imaging and Therapy in Europe
- Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT